|
1) Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007; 128: 683-92
|
|
|
|
2) Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007; 8: 286-98
|
|
|
|
|
|
3) Akashi K. Lineage promiscuity and plasticity in hematopoietic development. Ann NY Acad Sci. 2005; 1044: 125-31
|
|
|
|
|
|
4) Miyamoto T, Akashi K. Lineage promiscuous expression of transcription factors in normal hematopoiesis. Int J Hematol. 2005; 81: 361-7
|
|
|
|
|
5) Yagi S, Hirabayashi K, Sato S, et al. DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) in mouse promoter regions demonstrating tissue-specific gene expression. Genome Res. 2008; 18: 1969-78
|
|
|
|
|
|
6) Sato S, Yagi S, Arai Y, et al. Genome-wide DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) residing in mouse pluripotent stem cells. Genes to Cells. 2010; 15: 607-18
|
|
|
|
|
|
7) Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20: 85-93
|
|
|
|
|
|
8) Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002; 39: 6-11
|
|
|
|
|
|
9) Garcia-Manero G, Yang H, Kuang SQ, et al. Epigenetics of acute lymphocytic leukemia. Semin Hematol. 2009; 46: 24-32
|
|
|
|
|
|
10) Schuebel KE, Chen W, Cope L, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007; 3: 1709-23
|
|
|
|
|
|
11) Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-74
|
|
|
|
|
|
12) Taylor KH, Pena-Hernandez KE, Davis JW, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007; 67: 2617-25
|
|
|
|
|
|
13) Kuang SQ, Tong WG, Yang H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. 2008; 22: 1529-38
|
|
|
|
|
|
14) Roman-Gomez J, Agirre X, Jimenez-Velasco A, et al. Epigenetic regulation of micro RNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009; 27: 1316-22
|
|
|
|
|
|
15) Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. Epigenetic silencing of the tumor suppressor micro RNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009; 69: 4443-53
|
|
|
|
|
|
16) Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. Oncogene. 2010; 29: 3723-31
|
|
|
|
|
|
17) Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; Epub Ahead of Print
|
|
|
|
|
|
18) Davidsson J, Lilljebjorn H, Andersson A, et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet. 2009; 18: 4054-65
|
|
|
|
|
|
19) Milani L, Lundmark A, Kiialainen A, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood. 2010; 115: 1214-25
|
|
|
|
|
|
20) Scholz C, Nimmrich I, Burger M, et al. Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann Hematol. 2005; 84: 236-44
|
|
|
|
|
|
21) Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17: 13-27
|
|
|
|
|
|
22) Gutierrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. Leukemia. 2003; 17: 1845-50
|
|
|
|
|
|
23) Stumpel DJ, Schneider P, van Roon EH, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood. 2009; 114: 5490-8
|
|
|
|
|
|
24) Ishii E, Kawasaki H, Isoyama K, et al. Recent advances in the treatment of infant acute myeloid leukemia. Leuk Lymphoma. 2003; 44: 741-8
|
|
|
|
|
|
25) Eguchi M, Eguchi-Ishimae M, Greaves M. Molecular pathogenesis of MLL-associated leukemias. Int J Hematol. 2005; 82: 9-20
|
|
|
|
|
|
26) Birke M, Schreiner S, Garcia-Cuellar M-P, et al. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucl Acids Res. 2002; 30: 958-65
|
|
|
|
|
|
27) Erfurth FE, Popovic R, Grembecka J, et al. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci. 2008; 105: 7517-22
|
|
|
|
|
|
28) Cierpicki T, Risner LE, Grembecka J, et al. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol. 2010; 17: 62-8
|
|
|
|
|
|
29) Schafer E, Irizarry R, Negi S, et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 2010; 115: 4798-809
|
|
|
|
|
|
30) Ikawa Y, Sugimoto N, Koizumi S, et al. Dense methylation of types 1 and 2 regulatory regions of the CD10 gene promoter in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene. J Pediatr Hematol Oncol. 2010; 32: 4-10
|
|
|
|
|
|
31) Niitsu N, Hayashi Y, Sugita K, et al. Sensitization by 5-aza-2ʼ-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1 alpha, 25-dihydroxyvitamin D3. Br J Haematol. 2001; 112: 315-26
|
|
|
|
|
|
32) Shen L, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003; 101: 4131-6
|
|
|
|
|
|
33) Canalli AA, Yang H, Jeha S, et al. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leukemia Research. 2005; 29: 881-5
|
|
|
|
|
|
34) Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004; 104: 2492-8
|
|
|
|
|
|
35) Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood. 2009; 113: 6061-8
|
|
|
|
|